Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCREASE: D-aspartate in RR-MS
NCT03387046Phase 2Terminated
- Sponsor
- Merck KGaA
- Start
- Mar 2018
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of D-Aspartic Acid in relapsing-remitting multiple sclerosis (RRMS), sponsored by Merck KGaA. Started Mar 2018; status: terminated.
02
Drugs
D-Aspartic Acid
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03387046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387046.